AC Immune SA (ACIU)

NASDAQ: ACIU · Real-Time Price · USD

1.73

0.06 (3.59%)

At close: May 02, 2025, 12:30 PM

3.59% (1D)

Bid	1.71
Market Cap	170.68M
Revenue (ttm)	27.31M
Net Income (ttm)	-50.92M
EPS (ttm)	-0.59
PE Ratio (ttm)	-2.92
Forward PE	-2.3
Analyst	Buy

Ask	1.72
Volume	27,872
Avg. Volume (20D)	194,427
Open	1.75
Previous Close	1.67
Day's Range	1.70 - 1.77
52-Week Range	1.43 - 4.98
Beta	1.49

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The comp...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 23, 2016

Employees 133

Stock Exchange NASDAQ

Ticker Symbol ACIU

Website https://www.acimmune.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 479.71% from the latest price.

Stock Forecasts

Earnings Surprise

AC Immune SA has released their quartely earnings on Apr 30, 2025:

Revenue of $1.1M exceeds estimates by $765.39K, with Infinity% YoY growth.

EPS of -0.21 misses estimates by 0.00, with 0.00% YoY growth.

Why Price Moved

5 months ago

+13.42%

AC Immune shares are trading higher after the comp... Unlock content with Pro Subscription

7 months ago

+5.81%

AC Immune shares are trading higher after the company announced it will receive the second ReTain-related milestone payment under its agreement with Janssen Pharmaceuticals.

News

1 day ago · zacks.com

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.

1 month ago · zacks.com

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.

1 month ago · zacks.com

AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

New Strong Buy Stocks for March 5th

PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.

2 months ago · zacks.com

Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts ...